Characteristics Associated with Accelerated Lung Function Decline in a Primary Care Population with Chronic Obstructive Pulmonary Disease.


Journal

International journal of chronic obstructive pulmonary disease
ISSN: 1178-2005
Titre abrégé: Int J Chron Obstruct Pulmon Dis
Pays: New Zealand
ID NLM: 101273481

Informations de publication

Date de publication:
2020
Historique:
received: 31 08 2020
accepted: 06 11 2020
entrez: 3 12 2020
pubmed: 4 12 2020
medline: 29 6 2021
Statut: epublish

Résumé

Estimates for lung function decline in chronic obstructive pulmonary disease (COPD) have differed by study setting and have not been described in a UK primary care population. To describe rates of FEV Current/ex-smoking COPD patients (35 years+) who had at least 2 FEV A total of 72,683 and 50,649 COPD patients had at least 2 FEV Rate of FEV

Sections du résumé

Background
Estimates for lung function decline in chronic obstructive pulmonary disease (COPD) have differed by study setting and have not been described in a UK primary care population.
Purpose
To describe rates of FEV
Patients and Methods
Current/ex-smoking COPD patients (35 years+) who had at least 2 FEV
Results
A total of 72,683 and 50,649 COPD patients had at least 2 FEV
Conclusion
Rate of FEV

Identifiants

pubmed: 33268984
doi: 10.2147/COPD.S278981
pii: 278981
pmc: PMC7701160
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3079-3091

Subventions

Organisme : Medical Research Council
ID : MR/P021573/1
Pays : United Kingdom

Informations de copyright

© 2020 Whittaker et al.

Déclaration de conflit d'intérêts

HRW & JKQ received funding from GSK for this work. JKQ also reports grants from Asthma UK, personal fees from AZ, MRC, Chiesi, BI, and The Health Foundation, outside the submitted work. JMP is a full-time employee of GSK and holds shares in GSK. SJK reports personal fees from DIADEM and AstraZeneca, outside the submitted work. The authors report no other conflicts of interest in this work.

Références

Chest. 2012 Jan;141(1):222-231
pubmed: 22215830
Am J Respir Crit Care Med. 2018 Jan 1;197(1):47-55
pubmed: 28737971
Thorax. 2003 May;58(5):388-93
pubmed: 12728157
Am J Respir Crit Care Med. 1994 Oct;150(4):956-61
pubmed: 7921469
N Engl J Med. 1999 Jun 24;340(25):1948-53
pubmed: 10379018
Expert Rev Respir Med. 2014 Aug;8(4):515-21
pubmed: 24832442
Int J Chron Obstruct Pulmon Dis. 2015 Dec 30;11:51-60
pubmed: 26766907
N Engl J Med. 2011 Sep 29;365(13):1184-92
pubmed: 21991892
Int J Chron Obstruct Pulmon Dis. 2016 May 26;11:1097-103
pubmed: 27307725
Respir Res. 2019 Jul 2;20(1):135
pubmed: 31266489
Respir Res. 2011 Sep 28;12:129
pubmed: 21955733
Eur Respir J. 2002 Sep;20(3):665-73
pubmed: 12358345
Chest. 2003 Oct;124(4):1350-6
pubmed: 14555565
Thorax. 1993 Apr;48(4):375-80
pubmed: 8511735
BMJ Open. 2014 Jul 23;4(7):e005540
pubmed: 25056980
Thorax. 1999 Jul;54(7):581-6
pubmed: 10377201
Respir Med. 2017 Jul;128:85-91
pubmed: 28610675
Am J Respir Crit Care Med. 2017 Apr 15;195(8):1058-1065
pubmed: 27907454
Br J Gen Pract. 2018 Nov;68(676):e775-e782
pubmed: 30249612
Int J Chron Obstruct Pulmon Dis. 2015 Sep 07;10:1819-27
pubmed: 26379432
Am J Respir Crit Care Med. 2011 Nov 1;184(9):1015-21
pubmed: 21836135
Am Rev Respir Dis. 1981 Apr;123(4 Pt 1):378-81
pubmed: 7224350
Thorax. 1999 Dec;54(12):1119-38
pubmed: 10567633
Int J Epidemiol. 2015 Jun;44(3):827-36
pubmed: 26050254
J Am Coll Cardiol. 2018 Sep 4;72(10):1109-1122
pubmed: 30165982
Thorax. 2002 Oct;57(10):847-52
pubmed: 12324669
Am J Respir Crit Care Med. 2016 Mar 15;193(6):662-72
pubmed: 26695373
COPD. 2007 Dec;4(4):339-46
pubmed: 18027161
Am J Respir Crit Care Med. 2007 Mar 1;175(5):458-63
pubmed: 17158282
Am J Respir Crit Care Med. 2018 Aug 15;198(4):464-471
pubmed: 29474094
Am J Respir Crit Care Med. 2008 Aug 15;178(4):332-8
pubmed: 18511702
Thorax. 2011 Jan;66(1):49-54
pubmed: 20980245
Am J Respir Crit Care Med. 2001 Jan;163(1):61-8
pubmed: 11208627
Eur Respir J. 2017 Aug 10;50(2):
pubmed: 28798087
BMJ. 2000 May 13;320(7245):1297-303
pubmed: 10807619
Ann Am Thorac Soc. 2019 Jul;16(7):826-835
pubmed: 30908927
Chronic Obstr Pulm Dis. 2018 Apr 1;5(2):124-133
pubmed: 30374450
Am J Respir Crit Care Med. 2000 May;161(5):1608-13
pubmed: 10806163
Int J Epidemiol. 2004 Apr;33(2):271-8
pubmed: 15082626
BMC Pulm Med. 2019 Jul 12;19(1):127
pubmed: 31299936
COPD. 2016 Aug;13(4):425-30
pubmed: 26807738
Br Med J. 1977 Jun 25;1(6077):1645-8
pubmed: 871704
Sci Rep. 2019 Feb 14;9(1):2073
pubmed: 30765818
Lancet. 2016 Apr 30;387(10030):1817-26
pubmed: 27203508
Respir Res. 2019 Oct 29;20(1):236
pubmed: 31665000
Thorax. 2006 Jun;61(6):472-7
pubmed: 16517577
Am J Respir Crit Care Med. 2002 Sep 1;166(5):675-9
pubmed: 12204864
Eur Respir J. 2019 Mar 14;53(3):
pubmed: 30578401
Eur Respir J. 2010 Sep;36(3):480-7
pubmed: 20150201
BMC Pulm Med. 2019 Mar 14;19(1):62
pubmed: 30866890
Chest. 2007 Nov;132(5):1608-14
pubmed: 17998360
Int J Chron Obstruct Pulmon Dis. 2012;7:95-9
pubmed: 22371650
Respir Med. 2013 Dec;107(12):1904-11
pubmed: 23972968
Int J Chron Obstruct Pulmon Dis. 2015 Oct 13;10:2185-92
pubmed: 26508848
Int J Chron Obstruct Pulmon Dis. 2017 Jun 07;12:1663-1668
pubmed: 28652719
PLoS One. 2017 May 4;12(5):e0177032
pubmed: 28472184
Chest. 2007 Aug;132(2):464-70
pubmed: 17573503
Am J Respir Crit Care Med. 2017 Feb 1;195(3):324-330
pubmed: 27556408

Auteurs

Hannah R Whittaker (HR)

Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, London, UK.

Jeanne M Pimenta (JM)

Epidemiology (Value Evidence and Outcomes), GlaxoSmithKline, R&D, Uxbridge, UK.

Deborah Jarvis (D)

Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, London, UK.

Steven J Kiddle (SJ)

MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.

Jennifer K Quint (JK)

Respiratory Epidemiology, Occupational Medicine and Public Health, National Heart and Lung Institute, Imperial College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH